R

Regeneron Pharmaceuticals

Develops biopharmaceutical therapies for serious diseases

Principal Manufacturing Sciences and Technology Engineer

Full-TimeUpdated
$92.2k - $150.6k/yr
Senior, Expert
Bachelor's
East Greenbush, NY, USA
In PersonOn-site, Monday-Friday, 8am-4:30pm; 25-50% domestic and occasional international travel.
Biology & BiotechBioprocess & Biomanufacturing

About the job

Requirements
  • Bring demonstrated technical knowledge in drug product manufacturing, product development, and validation, along with experience interacting with Contract Manufacturing Organizations.
  • Apply strong knowledge of industry practices and regulations, including cGMP and Annex I, across multiple health authorities, including FDA, EMA, and MHRA.
  • A Bachelor's degree in Engineering, Chemical Engineering, or Biomedical Engineering is preferred.
  • Principal MSAT Engineer: 8 or more years of relevant experience; Staff MSAT Engineer: 10 or more years of relevant experience. Level is determined based on qualifications relevant to the role.
Responsibilities
  • Support and/or lead equipment selection, contract manufacturing organization selection strategy, equipment qualification, and process validation activities; solve issues hands-on during technology transfer and cGMP start-up.
  • Provide floor support during internal or external manufacturing operations, review process data to ensure operational consistency after process transfer, and support investigations.
  • Serve as technical lead and subject matter expert for drug product manufacturing process transfer, overseeing new product introduction, technology transfer, and process troubleshooting and issue resolution.
  • Track and report project milestones, including raw material and component procurement, equipment readiness, analytical transfer, and documentation; partner with or lead cross-functional internal and external teams to ensure successful transfer execution.
  • Review and approve cGMP batch documentation, including master batch records, specifications, and validation protocols; author policies, technical reports, protocols, and change controls supporting cGMP activities.
  • Monitor cGMP compliance at drug product contract manufacturers to protect product integrity and company reputation.
  • Trend process performance to establish and improve process capability, ensuring operations remain within the intended control strategy.
  • Investigate deviations, determine root causes, and identify and implement corrective and preventive actions; develop sampling plans for GMP batches, including lot release, stability, and characterization.
  • Collaborate with internal and external teams to identify and drive opportunities to improve process performance and cGMP operations.
  • Lead or assist with equipment selection, qualification, and start-up activities, and work with Manufacturing to ensure robust operating procedures.
  • Partner with Strategic Sourcing and Procurement to define technical requirements for raw materials, components, equipment, and services, ensuring on-time vendor delivery.
  • Work with DP MSAT management to define organizational structure, prioritize strategic initiatives, and assess staffing needs to support growth.
  • Use subject matter expertise to resolve emerging issues and escalate to line management as needed to manage impact.
Desired Qualifications
  • A Bachelor's degree in Engineering, Chemical Engineering, or Biomedical Engineering.

About the company

R

Regeneron Pharmaceuticals

View

Regeneron Pharmaceuticals develops and commercializes medicines for serious diseases, with a focus on cancer, eye diseases, allergic and inflammatory diseases, and infectious diseases. Its products come from using proprietary research capabilities and technologies to discover and develop therapies, often in collaboration with academic, research, and industry partners. Revenue comes from selling approved medicines and from licensing its technologies and entering co-development and co-commercialization partnerships. The company works with healthcare providers and regulators to ensure treatment delivery and safety. Its goal is to improve patient outcomes by bringing life-transforming medicines to market through rigorous R&D and strategic collaborations, maintaining leadership in biopharmaceutical innovation.

Company Size

10,001+

Company Stage

IPO

Headquarters

Town of Mount Pleasant, New York

Founded

1988

Get referred to Regeneron Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sanofi paid $1 billion upfront, with up to $7 billion more for Regeneron's immunology pipeline.
  • Q2 2026 revenue rose 17% to $4.3 billion; Dupixent sales hit $6.0 billion.
  • Libtayo and EYLEA HD both posted record sales in Q2 2026, widening diversification.

What critics are saying

  • EYLEA biosimilar competition starts in January 2027 after Samsung's settlement.
  • Regeneron faces a 2026 SDNY securities class action over the failed fianlimab melanoma trial.
  • Dupixent's patent cliff later this decade threatens the company's biggest profit pool.

What makes Regeneron Pharmaceuticals unique

  • VelocImmune keeps generating partnered immunology assets; Sanofi renewed the alliance on October 1, 2026.
  • Dupixent remains Regeneron's engine, with over 1.5 million patients across nine indications.
  • EYLEA HD conversion shows platform strength; U.S. sales hit $596 million in Q2 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Wellness Program
  • Paid Vacation
  • Equity Awards
  • Annual Bonuses
  • Flexible Work Hours

Growth & Insights and Company News

6 month growth

1%

1 year growth

12%

2 year growth

12%
Yahoo Finance
Oct 28th, 2026
Regeneron shares return 25.3% in a year, but is the $816 price too high?

Regeneron Pharmaceuticals shareholders earned a 25.3% return over the past year, including dividends. The shares now trade at $816, up from $585 at the start of the period. A bullish view put fair value at $722, assuming 5.4% annual revenue growth and a 30.1% profit margin. A cautious view put it at $540, citing margin strain from US healthcare reforms and biosimilars. The evidence cut both ways. Regeneron signed multibillion-dollar collaborations in radiopharmaceuticals and Helicon peptides, and expanded its work with Sanofi. But second-quarter net margin fell from 37.9% to 30.2%, with revenue at $4,290.7 million. At $816, the price assumes pipeline assets will offset pricing pressure and competition. Risks include heavy reliance on EYLEA and Dupixent, trial uncertainty, and lawsuits.

Yahoo Finance
Oct 27th, 2026
Regeneron pivots as EYLEA HD overtakes EYLEA, with Q2 revenue up 16.7%

Regeneron Pharmaceuticals has changed its message on its eye drugs. On its July 30, 2026 call, management said the newer EYLEA HD had outsold EYLEA for the first time. In February 2025, it focused on keeping EYLEA's market share. In the second quarter of 2026, US sales of EYLEA HD rose 52% from a year earlier, while EYLEA's fell 45%. EYLEA HD now makes up about 60% of US sales for the two drugs, against 34% a year earlier. Total revenue rose 16.7%, helped by higher Sanofi collaboration revenue, EYLEA HD and Libtayo. Management expects EYLEA demand to fall by a low to mid-teens percentage each quarter in the second half, partly due to biosimilars. The stock trades at 19.2 times earnings, against 22.9 for the S&P 500.

Yahoo Finance
Oct 26th, 2026
Regeneron to book full Dupixent profit share in Q3 after $930M repayment drag

Regeneron reports third-quarter results on October 30, and it will book its full share of Dupixent profits from Sanofi for the first time. Repayments of a development balance, which stood at about $3.1 billion in 2022, cut collaboration revenue by roughly $930 million in 2025. Last quarter, Regeneron posted non-GAAP earnings per share of $14.29 against an $8.00 consensus. Revenue rose 16.73% to $4.29 billion, and global Dupixent sales reached $6.00 billion, up 38%. The companies also expanded their alliance to up to $8 billion, adding four long-acting antibodies and settling prior litigation. Eylea HD US sales hit $596 million, up 52%, passing legacy Eylea for the first time. Analysts expect third-quarter revenue of $4.56 billion.

Yahoo Finance
Oct 21st, 2026
Regeneron trades at 19.2x earnings versus Amgen's 27.1x despite similar growth

Regeneron Pharmaceuticals trades at 19.2 times earnings for the four quarters ended June 30, 2026, well below Amgen's 27.1, though both grew revenue at a similar pace. Regeneron's revenue rose 9.3% against Amgen's 9.1%. Amgen has the higher operating margin, at 30.0% against 26.9%. Its shares also gained more over the past year, rising 51.0% against 40.4%. Regeneron's largest drug, EYLEA, is shrinking. Its revenue fell to $2.75 billion in fiscal 2025 from $4.77 billion, and management expects demand to fall further as biosimilars launch. Partners supply about half of revenue, and management expects Sanofi collaboration revenue to rise from fiscal Q3 2026. The next report is expected on or around October 30, 2026.

Yahoo Finance
Oct 19th, 2026
Regeneron's weight loss drugs could challenge Eli Lilly and Novo with 19% weight loss

Regeneron Pharmaceuticals could carve out a place in the fast-growing weight loss market, where Eli Lilly and Novo are expected to stay ahead for about five years. Its drug olatorepatide, licensed from a China-based company, mimics the GLP-1 and GIP hormones, as Lilly's Zepbound does. In a Phase 3 study in China, it led to mean weight loss of up to 19% over 48 weeks, with fewer stomach-related side effects than some rivals. Regeneron still needs US late-stage trials before approval. Its other candidate, trevogrumab, helps patients keep lean mass. In a Phase 2 study alongside Novo's semaglutide, lean mass preservation reached up to 42.5%, against 7.3% with semaglutide plus placebo. Second-quarter revenue rose 17% year over year to $4.3 billion, driven by eczema drug Dupixent.